# Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

> **NCT00802464** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 410 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Herpes zoster vaccine GSK1437173A
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00802464
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01-12
- **Primary completion:** 2010-07-02
- **Final completion:** 2010-07-02
- **Target enrollment:** 410 (ACTUAL)
- **Last updated:** 2019-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00802464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00802464, "Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00802464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*